AI assistant
ACADIA PHARMACEUTICALS INC — Director's Dealing 2021
Jan 8, 2021
31237_dirs_2021-01-08_4d3ba988-879d-44b6-bb75-726e886d274c.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ACADIA PHARMACEUTICALS INC (ACAD)
CIK: 0001070494
Period of Report: 2021-01-06
Reporting Person: KIM AUSTIN D. (EVP & General Counsel)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-01-06 | Common Stock | M | 1633 | — | Acquired | 6196 | Direct |
| 2021-01-06 | Common Stock | S | 678 | $53.34 | Disposed | 5518 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-01-06 | Restricted Stock Units | $ | M | 1633 | Disposed | Common Stock (1633) | Direct |
Footnotes
F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F2: Includes 712 shares of the Issuer's common stock acquired by the reporting person on November 13, 2020 pursuant to an employee stock purchase program.
F3: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units.
F4: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F5: The restricted stock units vest in four equal annual installments beginning January 6, 2021.